Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

February 7, 2023 06:35 AM ESTUpdated 07:39 AM

Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?